[go: up one dir, main page]

WO2012116210A2 - Peptide pour l'induction d'une immunotolérance en tant que traitement pour le lupus érythémateux disséminé - Google Patents

Peptide pour l'induction d'une immunotolérance en tant que traitement pour le lupus érythémateux disséminé Download PDF

Info

Publication number
WO2012116210A2
WO2012116210A2 PCT/US2012/026364 US2012026364W WO2012116210A2 WO 2012116210 A2 WO2012116210 A2 WO 2012116210A2 US 2012026364 W US2012026364 W US 2012026364W WO 2012116210 A2 WO2012116210 A2 WO 2012116210A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
cells
pcons
amino acid
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/026364
Other languages
English (en)
Other versions
WO2012116210A3 (fr
Inventor
Bevra H. Hahn
Brian J. SKAGGS
Ram Raj Singh
Fanny M. Ebling
Antonio La Cava
Ram Pyare Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2012116210A2 publication Critical patent/WO2012116210A2/fr
Publication of WO2012116210A3 publication Critical patent/WO2012116210A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Definitions

  • At least one amino acid moiety in the peptide is a D-amino acid; and/ or the peptide is in a head-to-tail cyclic configuration; and/ or multiple copies of the peptide are coupled to a polymeric matrix; and the peptide is capable of binding a T lymphocyte and/or modulating the immune response of an animal to whom the peptide is administered.
  • Such embodiments can use the peptide as probe for example to identify the presence of a T lymphocyte in a biological sample as a CD4+CD25- helper T lymphocyte.
  • the peptides of this invention comprising D- form amino acids can be administered, even orally, without protection against proteolysis by stomach proteases, etc.
  • peptide delivery can be enhanced by the use of protective excipients. This is typically accomplished either by complexing the polypeptide with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the polypeptide in an appropriately resistant carrier such as a liposome.
  • protective excipients is typically accomplished either by complexing the polypeptide with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the polypeptide in an appropriately resistant carrier such as a liposome.
  • Means of protecting polypeptides for oral delivery are well known in the art (see, e.g., U.S. Pat. No. 5,391,377 describing lipid compositions for oral delivery of therapeutic agents).
  • Spleen cells were isolated from saline-treated, naive or tolerized, BWF1 mice one- week after administration of pCons after lysis of red blood cells with ACK lysing buffer (Sigma, St. Louis, MO). Cell subsets were purified by incubation with anti-CD4, anti- B and anti-CD8+, anti NKl.l, anti Mac-3, anti Gr-1, microbeads from (Miltenyi Biotech, Auburn, CA). A total of lx 2 x 10 6 freshly isolated spleen cells or CD8 + T cells were used for staining of cell surface molecules. Antibodies used to analyze the cells included anti-Thyl.2, Anti-CD4, Anti-B220, anti-CD8, anti-CD25 and anti-CD28 (all from BD Pharmingen, San Diego, CA).
  • Isolated cells were washed with FACS buffer and 1-2 million cells were used for surface staining and immunophenotyping. Before staining, cells were incubated with rat anti-mouse CD16/CD32 (FCy III/II receptor) monoclonal antibody to block- nonspecific binding.
  • Stimulatory control peptides B and D are wild peptides from human mAb anti-DNA; peptide A is a nonstimulatory negative control (see, e.g. Kalsi et al., Lupus 2004; 13:490-500).
  • addition of pCons or peptides B and D to cultures of SLE T cells expanded CD4+CD25hi populations in some patients (and in some controls: we have not found a stimulatory Ig peptide that is exclusively recognized by SLE patients).
  • the TGF l Quantikine ELISA kit (R&D Systems, MBIOOB) was utilized to determine serum TGFP levels. 5 ⁇ serum from individual animals in each treatment group at each timepoint were pooled (40 ⁇ total) and acid activated per the manufacturer's directions. Samples were diluted and assayed in duplicate exactly as described by the manufacturer. Prism was used to construct a TGF standard curve and identify unknown sample TGF concentrations. Cumulative TGF levels over all timepoints were graphed using Prism.
  • Prism 4 software (GraphPad) was used for all statistical determinations. Testing between two groups (unfed control or DMSO-fed control versus individual treatment groups) was performed using the Mann- Whitney U test for proteinuria, anti-dsDNA antibody titer, total serum IgG, and TGF concentration. Cox regression was performed for survival curves. R values ⁇ 0.05 were considered significant.
  • pCons peptide variants and feeding schedule We were initially concerned that linear pCons would be sensitive to gut peptidases and proteases, as it is constructed of L-amino acids (see, e.g. Navab et al., Circulation. 2002;105:290-2). Therefore, we utilized a version of pCons in which every amino acid (except for the glycine at position 12) is a D-amino acid (D-pCons). Cyclic peptides such as the immunosuppressant cyclosporine, where the N- and C-termini are linked via a standard peptide bond, are more stable to proteolytic degradation (see, e.g.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des peptides d'acide aminé comprenant la séquence FIEWNKLRFRQGLEW et leur utilisation dans des procédés pour le diagnostic et/ou le traitement de troubles immunitaires tels que le lupus érythémateux disséminé. Typiquement, au moins un fragment d'acide aminé dans le peptide est un acide aminé D ; et/ou le peptide est dans une configuration cyclique tête à queue ; et/ou des copies multiples du peptide sont couplées à une matrice polymère non immunogène telle que la polylysine (en tant que peptide antigène multiple ou MAP). Typiquement, le peptide est capable d'inhiber la production d'auto-anticorps qui se lient à de l'ADN bicaténaire chez un mammifère ayant le lupus érythémateux disséminé (SLE).
PCT/US2012/026364 2011-02-23 2012-02-23 Peptide pour l'induction d'une immunotolérance en tant que traitement pour le lupus érythémateux disséminé Ceased WO2012116210A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445769P 2011-02-23 2011-02-23
US61/445,769 2011-02-23

Publications (2)

Publication Number Publication Date
WO2012116210A2 true WO2012116210A2 (fr) 2012-08-30
WO2012116210A3 WO2012116210A3 (fr) 2013-01-31

Family

ID=46721460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/026364 Ceased WO2012116210A2 (fr) 2011-02-23 2012-02-23 Peptide pour l'induction d'une immunotolérance en tant que traitement pour le lupus érythémateux disséminé

Country Status (1)

Country Link
WO (1) WO2012116210A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019174104A1 (fr) * 2018-03-13 2019-09-19 江苏浩欧博生物医药股份有限公司 Kit de mesure d'un anticorps anti-peptide citrulliné cyclique, son application et procédé de test

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903184B1 (en) * 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
JP2003516526A (ja) * 1999-11-28 2003-05-13 ラ ホヤ ファーマシューティカル カンパニー 抗体親和性に基づいて狼瘡を処置する方法およびスクリーニング方法ならびにその使用のための組成物
WO2009052415A1 (fr) * 2007-10-17 2009-04-23 The Regents Of The University Of California Peptide destiné à l'induction d'une tolérance immunitaire en tant que traitement pour le lupus érythémateux systémique
EP2284188B1 (fr) * 2009-07-31 2012-07-04 Toscana Biomarkers S.r.l. Détection d'anticorps de protéine P anti-ribosomale au moyen de peptides synthétiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019174104A1 (fr) * 2018-03-13 2019-09-19 江苏浩欧博生物医药股份有限公司 Kit de mesure d'un anticorps anti-peptide citrulliné cyclique, son application et procédé de test

Also Published As

Publication number Publication date
WO2012116210A3 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
US11926671B2 (en) Antibodies and polypeptides directed against CD127
ES2973062T3 (es) Anticuerpos anti-CD40 y usos de los mismos
CN104774261B (zh) Foxm1 肽和包含foxm1 肽的药剂
CN105307725B (zh) 治疗自身免疫疾病的方法和组合物
WO2010070047A1 (fr) Polypeptides solubles pour application au traitement de troubles auto-immuns et inflammatoires
US10421809B2 (en) Anti-TLR4 antibodies and uses thereof
US20200397855A1 (en) Modulation of pla2-g1b in therapy
US8492347B2 (en) Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
EP2356222A2 (fr) Cellules t tueuses naturelles foxp3 et traitement des maladies associées à l'immunité
US11603387B2 (en) SOCS mimetics for the treatment of diseases
KR20200115490A (ko) 신규한 용도
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
US12226449B2 (en) Materials and methods for the prevention of rheumatoid arthritis
WO2012116210A2 (fr) Peptide pour l'induction d'une immunotolérance en tant que traitement pour le lupus érythémateux disséminé
UA110119C2 (xx) Пептиди tomm34 та вакцини, що їх містять
TW201138803A (en) ECT2 peptides and vaccines including the same
AU2016298108B2 (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
CN114349857B (zh) 一种Treg细胞制备方法以及在自身免疫性疾病方面的应用
US20220306722A1 (en) Peptides that block presentation of antigenic islet peptides by hla-dq8 and methods for treating type-1 diabetes
CN114605553A (zh) 含有Treg细胞的药物组合物以及在自身免疫性疾病中的用途
Hestvik Pathogenic and therapeutic aspects of intrathecal immune responses in multiple sclerosis
US20110229496A1 (en) Method for regulating survival and memory of t helper 1 cells
OA19665A (en) Antibodies and polypeptides directed against CD127.
EP3430056A1 (fr) Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine alpha 8 beta 1
EA041126B1 (ru) Антитела и полипептиды, направленные против cd127

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12749171

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12749171

Country of ref document: EP

Kind code of ref document: A2